Article written

  • on 18.11.2014
  • at 12:00 AM
  • by admin

Switzerland : FDA approves Roche s Avastin plus chemotherapy to treat women with platinum-resistant recurrent ovarian cancer [TendersInfo (India)]

Nov18

Roche, today announced that the U.S. Food and Drug Administration (FDA) approved Avastin (bevacizumab) in combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ovarian cancer. The approval was based on results from the Phase III AURELIA study that showed Avastin plus chemotherapy reduced the risk of disease worsening or death (progression-free survival or PFS) by 62 percent compared to women who received chemotherapy alone (median PFS: 6.8 vs. 3.4 months, Hazard Ratio (HR)=0.38; p
(c) 2014 Euclid Infotech Pvt. Ltd. Provided by SyndiGate Media Inc. (Syndigate.info).

subscribe to comments RSS

Comments are closed